Dermatologica Sinica

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 38  |  Issue : 1  |  Page : 3--8

Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata


Ying-Xiu Dai1, Chen-Pu Yeh1, Chih-Chiang Chen2 
1 Department of Dermatology, Taipei Veterans General Hospital; Department of Dermatology, School of Medicine, National Yang-Ming University, Taipei, Taiwan
2 Department of Dermatology, Taipei Veterans General Hospital; Department of Dermatology, School of Medicine; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

Correspondence Address:
Chih-Chiang Chen
Department of Dermatology, Taipei Veterans General Hospital, Taipei; Department of Dermatology, School of Medicine and Institute of Clinical Medicine, National Yang-Ming University, Taipei. No. 201, Sec. 2, Shipai Rd, Beitou District, Taipei City 11217
Taiwan

Background: Patients with severe alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU), are usually resistant to treatment. While tofacitinib is emerging as a promising therapy for severe AA, little is known about its efficacy and safety in Asians. Objectives: To evaluate the efficacy and safety of tofacitinib for treating severe AA. Methods: We included patients with ≥50% scalp hair loss, disease for ≥6 months, and tofacitinib therapy for ≥4 months. The efficacy, evaluated based on the percent change in severity of alopecia tool (SALT) score, and response time, defined as time from baseline to reach >50% improvement in SALT score, were assessed. Results: We included 35 patients (21 with AA, 3 with AT, and 11 with AU). There were 18 men and 17 women (median age: 39 [range: 12–68] years). After 4–24 months of treatment, 74.3% showed clinical response, with 51.4% of the patients achieving ≥50% hair regrowth. Patients with AA showed higher percent change in SALT score than patients with AT/AU (median [interquartile range]: 60.7% [0–98.2] vs. 41.1% [8.9–98.7], P = 0.047). Initial SALT score was negatively associated with the latest percent change in SALT score (P = 0.025). Duration of disease and current episode were positively associated with response time to tofacitinib (P = 0.018 and 0.026, respectively). Patients tolerated tofacitinib well without serious adverse events. Conclusion: Tofacitinib effectively promoted hair regrowth in Asian patients with severe AA. Randomized controlled trials with larger sample size are needed to confirm the long-term efficacy and safety of tofacitinib for treating severe AA.


How to cite this article:
Dai YX, Yeh CP, Chen CC. Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata.Dermatol Sin 2020;38:3-8


How to cite this URL:
Dai YX, Yeh CP, Chen CC. Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata. Dermatol Sin [serial online] 2020 [cited 2021 Sep 16 ];38:3-8
Available from: https://www.dermsinica.org/article.asp?issn=1027-8117;year=2020;volume=38;issue=1;spage=3;epage=8;aulast=Dai;type=0